Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lumena Pharmaceuticals

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

Shire wins FDA approval for haemophilia dosing software

The web-based myPKFiT supports the pharma firm's Advate treatment

- PMLiVE

Shire claims EU approval for haemophilia A drug Adynovi

The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share

- PMLiVE

Shire separates out neuroscience as it considers its future

Follows last year's strategic review at the Irish biotechnology firm

Shire Basingstoke

Shire’s Maribavir wins US breakthrough therapy designation

It's based on phase II data for the transplant infection treatment

- PMLiVE

Shire suffers pipeline failure as takeover speculation builds

Several big pharma companies are reportedly considering bids

Andy Busch joins Shire as its CSO and head of research and development

And Howard Mayer is promoted to chief medical officer

Bayer symbol

Joerg Moeller to head Bayer R&D after operational shake-up

Andreas Busch to move to Shire as head of R&D and CSO

- PMLiVE

Thomas Dittrich takes up CFO role at Shire

He also joins the Irish biotech’s board

- PMLiVE

Shire wins CHMP backing for Adynovi

Haemophilia A treatment backed for European approval

Magic of Lucid targets rare and specialist diseases

Lucid Group, the award-winning global medical communications company with offices in London, Buckinghamshire, Macclesfield and New York, has announced the launch of a new agency specialising in rare and specialist...

Lucid Group Communications Limited

- PMLiVE

Shire’s gene therapy candidate receives orphan drug status in the US

Investigational factor VIII treatment SHP654 is being developed for haemophilia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links